Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercè Boada Rovira

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Revista De Neurologia|June 3, 2010
[Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer's disease]Mercè Boada-Rovira
Medicina Clinica|June 12, 2003
[Genetics and Alzheimer disease]Agustín Codina Puiggrós, Mercè Boada Rovira
Drugs & Aging|January 13, 2004
Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience studyMercè Boada-Rovira, Henry Brodaty, Patrick Cras, et al.
Journal of Alzheimer'S Disease : JAD|October 30, 2014
Prevention of Alzheimer's disease: a global challenge for next generation neuroscientistsOctavio Rodríguez-Gómez, M Eugenia Palacio-Lacambra, Antoni Palasí, et al.
Journal of Clinical and Experimental Neuropsychology|January 15, 2009
Detection of visuoperceptual deficits in preclinical and mild Alzheimer's diseaseMontse Alegret, Mercè Boada-Rovira, Georgina Vinyes-Junqué, et al.
Frontiers in Genetics|January 1, 2024
Attitudes toward pre-symptomatic screening for Alzheimer's dementia in five European countries: a comparison of family members of people with Alzheimer's dementia <i>versus</i> non-family membersIoanna A Angelidou, Marina Makri, Konrad Beyreuther, et al.
Drugs|September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 TrialSusan Abushakra, Aidan Power, David Watson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 30, 2009
Creating a transatlantic research enterprise for preventing Alzheimer's diseaseZaven S Khachaturian, Jordi Camí, Sandrine Andrieu, et al.
Brain, Behavior, and Immunity|July 6, 2026
Temelimab versus placebo in patients with post-COVID conditionMayssam Nehme, Margret Hund-Georgiadis, Esther Del Corral Beamonte, et al.
The Lancet. Neurology|February 16, 2024
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disordersGiovanni B Frisoni, Cristina Festari, Federico Massa, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Revista De Neurologia|June 3, 2010
[Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer's disease]Mercè Boada-Rovira
Medicina Clinica|June 12, 2003
[Genetics and Alzheimer disease]Agustín Codina Puiggrós, Mercè Boada Rovira
Drugs & Aging|January 13, 2004
Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience studyMercè Boada-Rovira, Henry Brodaty, Patrick Cras, et al.
Journal of Alzheimer'S Disease : JAD|October 30, 2014
Prevention of Alzheimer's disease: a global challenge for next generation neuroscientistsOctavio Rodríguez-Gómez, M Eugenia Palacio-Lacambra, Antoni Palasí, et al.
Journal of Clinical and Experimental Neuropsychology|January 15, 2009
Detection of visuoperceptual deficits in preclinical and mild Alzheimer's diseaseMontse Alegret, Mercè Boada-Rovira, Georgina Vinyes-Junqué, et al.
Frontiers in Genetics|January 1, 2024
Attitudes toward pre-symptomatic screening for Alzheimer's dementia in five European countries: a comparison of family members of people with Alzheimer's dementia <i>versus</i> non-family membersIoanna A Angelidou, Marina Makri, Konrad Beyreuther, et al.
Drugs|September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 TrialSusan Abushakra, Aidan Power, David Watson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 30, 2009
Creating a transatlantic research enterprise for preventing Alzheimer's diseaseZaven S Khachaturian, Jordi Camí, Sandrine Andrieu, et al.
Brain, Behavior, and Immunity|July 6, 2026
Temelimab versus placebo in patients with post-COVID conditionMayssam Nehme, Margret Hund-Georgiadis, Esther Del Corral Beamonte, et al.
The Lancet. Neurology|February 16, 2024
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disordersGiovanni B Frisoni, Cristina Festari, Federico Massa, et al.
Pageof 1